

MEETING ABSTRACT

Open Access

EHMTI-0227. Therapeutic effectiveness of sphenopalatine ganglion (SPG) stimulation for cluster headache – pathway registry study interim results at 6 months

TP Jürgens^{1*}, R Jensen², H Kaube³, A Böger⁴, C Gaul⁵, A Goodman⁶, A Caparso⁶, A May¹

From 4th European Headache and Migraine Trust International Congress: EHMTIC 2014 Copenhagen, Denmark. 18-21 September 2014

Background

The Pathway Registry is an open label registry of SPG stimulation therapy for cluster headache treatment. In a previous randomized, double-blind, multi-center study (Pathway CH-1 study) 68% of patients experienced clinically significant improvements.

Aim

The aim of this interim analysis is to evaluate acute and/or preventive therapeutic effectiveness at 6 months following insertion of an SPG neurostimulator.

Method

Therapeutic effectiveness (acute pain response following SPG stimulation and/or attack frequency reduction) was analyzed during the first six months following SPG neurostimulator insertion. Acute pain responders achieved relief from moderate or greater pain, or freedom from mild pain in $\geq 50\%$ of analyzable attacks (with completed diary questions). Frequency responders achieved $\geq 50\%$ attack frequency reduction at the six month study visit (evaluated over the previous four weeks), versus the 4 week baseline period.

Results

49 patients have been enrolled, 18 completed follow-up through six months[RJ1] (189 days post-insertion, range 149-238). Average baseline attack frequency was 28.4 attacks/week (range 0-70), and the average attack frequency at 6 months was 17.3 attacks/week (range 0-70),

a 40% reduction. 67% (12/18) were responders. Of the 12 responders, 67% (N=8) were acute responders, treating 86% of their attacks effectively (N=546). 75% (N=9) were frequency responders; frequency reduced by 90% (from 22.3 at baseline to 2.1 (range 0-8) attacks/week). 5 patients were both acute and frequency responders.

Conclusion

Interim data from a registry of cluster headache patients continues to demonstrate the effectiveness of SPG stimulation therapy.

Authors' details

¹Headache Clinic Dept. of Systems Neuroscience, Medical Center Hamburg-Eppendorf, Hamburg, Germany. ²Danish Headache Center, Glostrup Hospital University of Copenhagen, Copenhagen, Denmark. ³Neurologie und Kopfschmerzzentrum Muenchner Freiheit, Neurologie und Kopfschmerzzentrum Muenchner Freiheit, Munich, Germany. ⁴Schmerzzentrum, Rotes Kreuz Krankenhaus, Kassel, Germany. ⁵Migräne und Kopfschmerzambulanz, Migräne und Kopfschmerzambulanz, Königstein, Germany. ⁶Autonomic Technologies Inc., Autonomic Technologies Inc., Redwood City California, USA.

Published: 18 September 2014

doi:10.1186/1129-2377-15-S1-C26

Cite this article as: Jürgens et al.: EHMTI-0227. Therapeutic effectiveness of sphenopalatine ganglion (SPG) stimulation for cluster headache – pathway registry study interim results at 6 months. *The Journal of Headache and Pain* 2014 15(Suppl 1):C26.

¹Headache Clinic Dept. of Systems Neuroscience, Medical Center Hamburg-Eppendorf, Hamburg, Germany

Full list of author information is available at the end of the article